Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Stephanie C, Read"'
Autor:
Simon J. Tulloch, Allan K. Chrisman, Joseph Biederman, Timothy E. Wilens, Richard H. Weisler, Thomas J. Spencer, Stephen V. Faraone, Stephanie C Read
Publikováno v:
CNS Spectrums. 11:625-639
Introduction:Attention-deficit/hyperactivity disorder (ADHD) is a serious neurobehavioral disorder of childhood onset that often persists into adolescence and adulthood. Functional impairments, underachievement, and difficult interpersonal relationsh
Autor:
Daniel F. Connor, Samuel W. Boellner, Howard Abikoff, Thomas J. Spencer, Raymond D. Pratt, Stephanie C Read, Joseph Biederman, Steven R. Pliszka
Publikováno v:
Clinical Therapeutics. 28:402-418
Oppositional defiant disorder (ODD)is associated with a high degree of impairment in social skills, family interaction, and academic functioning. Comorbid ODD is reportedly present in 40% to 70% of children and adolescents with attention-deficit/hype
Autor:
Raymond D. Pratt, Joseph Biederman, Richard H. Weisler, Timothy E. Wilens, Thomas J. Spencer, Stephanie C. Read
Publikováno v:
Clinical Therapeutics. 28:266-279
The ability to recognize and diagnose attention-deficit/hyperactivity disorder (ADHD) has increased in recent years. The persistence of ADHD symptoms puts adolescents with ADHD at risk for long-term adverse psychosocial outcomes.The primary goal of t
Autor:
Stephanie C Read, Thomas J. Spencer, Timothy E. Wilens, Joseph Biederman, Simon J. Tulloch, Richard H. Weisler
Publikováno v:
CNS Spectrums. 10:16-25
Objective: Assess the long-term safety and effectiveness of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit/hyperactivity disorder (ADHD) combined subtype.Methods: A 24-month, open-label extension of a 4-week, multi
Publikováno v:
CNS Spectrums. 10:6-15
Objectives: Assess the bioavailability of mixed amphetamine salts extended-release (MAS XR) 30-mg capsules and the dose proportionality of pharmacokinetic measures for MAS XR 20,40, and 60 mg.Methods: Study A, an open-label single-period study, and S
Publikováno v:
CNS Spectrums. 10:6-13
ObjectiveA randomized, open-label, single-dose, three-treatment, three-period, crossover, phase I study was conducted to assess the pharmacokinetics of mixed amphetamine salts extended release (MAS XR) in adolescents with attention-deficit/hyperactiv
Publikováno v:
CNS spectrums. 10(12 Suppl 20)
Assess the bioavailability of mixed amphetamine salts extended-release (MAS XR) 30-mg capsules and the dose proportionality of pharmacokinetic measures for MAS XR 20, 40, and 60 mg.Study A, an open-label single-period study, and Study B, a randomized